Related Experiment Videos

Anticardiolipin antibodies, recurrent stroke and vascular events: a prospective study on 210 patients

R Tănăsescu1, Marina Ticmeanu, Adriana Nicolau

  • 1Department of Neurology, Colentina Hospital, Bucharest, Romania. radut72@hotmail.com

Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne
|June 3, 2006
PubMed

Insights

Anticadiolipin antibodies (aCL) presence did not significantly predict recurrent ischemic stroke or thrombotic events in Romanian patients. Further research is needed for specific antiphospholipid antibody subtypes to identify higher-risk individuals.

Area of Science:

  • Neurology
  • Immunology
  • Cardiology

Background:

  • Anticadiolipin antibodies (aCL) are linked to vascular occlusive events, but their predictive role for ischemic stroke remains debated.
  • The association between aCL and thrombotic disease or recurrent stroke risk requires further investigation.

Purpose of the Study:

  • To determine if anticadiolipin antibodies (aCL) are associated with thrombotic disease or an increased risk of recurrent stroke.
  • To investigate the prevalence of cardiovascular risk factors in aCL-positive versus aCL-negative stroke patients.

Main Methods:

  • Prospective study on a Romanian cohort of stroke patients tested for aCL.
  • Analysis of cardiovascular risk factors, patient age, and 12-month medical evolution in aCL-positive and aCL-negative subgroups.
  • Assessment of antiphospholipid syndrome criteria fulfillment and aCL titer variability.

Main Results:

  • No significant differences in thrombotic event history, abortions, clinical/biological profiles, or vascular event recurrence were observed between aCL-positive and aCL-negative groups.
  • Antiphospholipid syndrome criteria were met in only two patients.
  • Variability in aCL titers was noted in 37% of cases at 8 weeks post-stroke.

Conclusions:

  • The study found no significant association between anticadiolipin antibodies and increased risk of recurrent ischemic events in the studied cohort.
  • The variability of aCL titers suggests a need for more specific antiphospholipid antibody subtypes to identify patients at higher risk of ischemia.
  • Further research is warranted to identify specific antiphospholipid antibody markers for thrombophilia.

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...